Cancer & Blood Diseases

Theme leader: John Zalcberg, Gail Risbridger & Peter Briggs

Monash Partners supports a catchment population of 1.45 million people and meets 27% of Victoria’s cancer service demand. Monash Partners provides cancer services and has aligned its Cancer and Blood Diseases Theme with the integration of the government-funded Southern Metropolitan Integrated Cancer Service (SMICS) and the Monash Comprehensive Cancer Consortium (MCCC) located at Monash University's Clayton campus. 

While clinical services in cancer reflect population needs, research has focused on three main specialities, each of which is supported by detailed cancer registries. The main research focuses in solid tumours cancer are prostate cancer – with a strong link between Monash University and the clinical services; colorectal cancer – with a significant research node at Cabrini Health; and lung cancer, which is a strong focus at Monash Health and the Hudson Institute of Medical Research. 

Blood diseases are the clinical and research field in which Monash Partners has a national leadership role. Integrated across Alfred and Monash Health and supported by Monash University, the Australian Centre for Blood Diseases (ABCD) is Australia’s largest academic clinical haematology group, providing the most extensive network of haematology services.

The team has led the national research agenda in multiple myeloma, acute myeloid leukaemia, thrombosis and in transplantation survivorship.

State-wide facilities include the Victorian Adult Haemophilia Treatment Centre (Alfred Health), the Victorian Haemoglobinopathy Reference Lab and Thalassemia service (Monash Health) and the state-wide bone marrow transplant service.

Future Goals:

This theme will:

1.     Continue to develop national cancer registries in conjunction with Monash University – in particular for blood cancers and thrombosis

2.     Leverage the facilities available through the new Monash Health Translation Precinct (MHTP), to broaden the scope of cancer research within Monash Partners

3.     Extend investigator-initiated phase I clinical trials of novel therapeutics for acute leukaemia and multiple myeloma

4.     Lead national-international randomised phase III clinical trials for cancer and blood diseases

5.      Development a Clinical/PhD training program in translational haematology.